In Cleburne, Medicaid payments for services under HCPCS codes specifically related to COVID-19 amounted to at least $127,057 in 2024, according to the U.S. Department of Health and Human Services Medicaid Provider Spending database.
Medicaid, overseen by the states and jointly financed by federal and state governments, insures low-income individuals and families, seniors, children and people with disabilities, marking it as a core part of the U.S. health care system. More details are available at this explainer.
Since Medicaid is taxpayer-funded, trends in local billing reflect how communities spend public health resources.
This analysis uses HCPCS codes identified as “COVID-19” or “coronavirus” in billing or reference data, which means these payment totals represent only services directly labeled as COVID-related—and exclude pandemic services billed under broader medical codes.
For context, Houston reported the highest Texas Medicaid payment total for COVID-related services in 2024, reaching $5,684,946 in virus-designated claims.
Three providers in Cleburne filed Medicaid claims for COVID-19–specific services in 2024. Immunoassay was among the leading codes billed, accounting for $77,311.
The average Medicaid payment per Cleburne provider for COVID-19 services was $42,352, compared with a statewide average of $40,722.
During the pandemic years, spending on COVID-19 services made up a significant share of the growth in Medicaid payments in Cleburne.
Medicaid payments in all other service categories grew by $5,735,910 from 2020 to 2024, a 650.7% rise.
In the two years before the pandemic, Cleburne’s average Medicaid payment each year was $352,586.
Centers for Medicare & Medicaid Services data show federal and state Medicaid spending reached about $871.7 billion in fiscal 2023, roughly 18% of all national health expenditures, up from around $613.5 billion in 2019, prior to the COVID-19 emergency.
This represents an approximate 40% gain over several years, driven by broader enrollment and higher usage throughout and after the pandemic.
Federal budget measures during the Trump administration included new plans to decrease Medicaid funding and alter the program structure. One recent policy, the “One Big Beautiful Bill Act,” passed in 2025, is projected to cut federal Medicaid outlays by more than $1 trillion during the next decade, through changes like work requirements and increased beneficiary cost-sharing. These adjustments are likely to shift greater costs to states and slow federal Medicaid support growth while the program continues serving millions of Americans.
| Year | COVID-19–Related Payments | COVID-19 Payments % Change (YoY) | Total Medicaid Payments |
|---|---|---|---|
| 2024 | $127,057 | -22.1% | $6,744,513 |
| 2023 | $163,126 | 8.7% | $6,427,300 |
| 2022 | $150,024 | 86.7% | $5,596,473 |
| 2021 | $80,377 | 944.3% | $4,419,423 |
| 2020 | $7,697 | N/A | $889,244 |
| 2019 | $0 | N/A | $342,316 |
| 2018 | $0 | N/A | $362,856 |
| HCPCS Code | Description | Medicaid Payments | Claims |
|---|---|---|---|
| 87811 | Immunoassay | $77,311 | 2,060 |
| 87635 | COVID Specific | $46,872 | 504 |
| U0002 | COVID Specific | $2,873 | 64 |
Note: Includes only HCPCS codes expressly flagged for COVID-19 services; totals exclude pandemic health care costs not specifically labeled as such.
The U.S. Department of Health and Human Services Medicaid Provider Spending database served as the primary source for this report. The dataset is accessible here.










